Neglected Tropical Disease Treatment Market Size, Revenue, Trend Report 2026 to 2035
What is Neglected Tropical Disease Treatment Market Size?
Global Neglected Tropical Disease Treatment Market Size is valued at USD 3.61 billion in 2025 and is predicted to reach USD 6.33 billion by the year 2035 at a 6.00% CAGR during the forecast period for 2026 to 2035.
Neglected Tropical Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class (Anti-Parasite, Antifungal, Antibiotics, Others), By Disease Type (Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Others), By Distribution Channel (Direct Sales, Indirect Sales), By Region, And By Segment Forecasts, 2026 to 2035
Neglected Tropical Disease Treatment Market Key Takeaways:
|
Neglected tropical disease treatment describes medical approaches and activities, such as medication, vaccinations, and public health campaigns, that are intended to address infectious diseases that largely impact underprivileged communities in tropical countries. The market for neglected tropical disease treatment products is being propelled forward by the increasing frequency of these diseases in developing nations due to several factors, including poor hygiene and a lack of access to necessary services like clean water. Additionally, the continuous investments made by pharmaceutical companies in research and development play a major role in the expansion of the industry. Moreover, the market for treating neglected tropical diseases depends on infrastructure upgrades. Improving medical facilities facilitates more efficient service delivery, expands access to therapies, and aids in continuing disease control and surveillance initiatives, all of which will enhance overall market growth in the coming years.
However, the high cost of treatment, lack of expertise, and poor healthcare infrastructure are slowing down the market growth. Additionally, the COVID-19 epidemic delayed diagnosis and treatment initiatives, therefore distorting the neglected tropical disease treatment market by redirecting healthcare resources and attention. However, strong health systems and faster developments in telemedicine and healthcare delivery are needed. In addition, there is rising growth in the healthcare sector, rising government incentives, and more investment in the neglected tropical disease treatment market.
Competitive Landscape
Some Major Key Players In The Neglected Tropical Disease Treatment Market:
- Thermo Fisher Scientific, Inc.
- Hoffmann-La Roche Ltd.
- Omega Diagnostics Group PLC
- Abbott
- Oscar Medicare Pvt. Ltd.
- Merck Ltd.
- Genome Diagnostics Pvt. Ltd.
- ZeptoMetrix
- Bayer AG,
- GlaxoSmithKline plc
- Novartis AG
- Pfizer, Inc.
- Eisai Co. Ltd.
- Sanofi
- Astellas Pharma
- Takeda Pharmaceutical Company Limited
- Gilead Sciences
- Other Market Players
Market Segmentation:
The neglected tropical disease treatment market is segmented based on drug class, disease type, distribution channel. As per the drug class, the market is classified into anti-parasite, antifungal, antibiotics, and others. By disease type, the market is segmented into leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and others. The distribution channel segment comprises direct sales and indirect sales.
According To The Drug Class, The Antibiotics Segment Accounts For A Major Contributor To The Neglected Tropical Disease Treatment Market.
Antibiotics in the neglected tropical disease treatment market are expected to hold a major global market share in 2023 because of their essential part in preventing bacterial infections connected to these disorders. Demand is driven in part by growing awareness of drug-resistant strains and more healthcare campaigns to fight these diseases. Furthermore, enhancing antibiotic accessibility and efficacy is a continuous research and development initiative that is driving this market growth.
The Leishmaniasis Segment To Witness Growth At A Rapid Rate
The leishmaniasis segment is growing rapidly because of the growing worldwide travel and migration that help the disease spread. Additionally, higher detection rates are the result of growing knowledge and better diagnosis methods. Moreover, improved government and non-governmental support for research and control initiatives is accelerating the development and implementation of successful treatments, therefore stimulating expansion in this market sector.
In The Region, The Asia Pacific Neglected Tropical Disease Treatment Market Holds A Significant Revenue Share.
The Asia Pacific neglected tropical disease treatment market is expected to note the highest revenue share in the near future. This can be attributed to large investments in research and development, excellent healthcare infrastructure, strong government support for disease elimination, and heightened public health awareness. In addition, North America is projected to grow very fast in the neglected tropical disease treatment market because of growing healthcare expenditures, higher disease prevalence, more treatment accessibility, and more government projects aiming at disease control innovation in healthcare technology.
Recent Developments:
- In Feb 2024, Takeda established a strategic relationship with Biological E. Limited, a prominent vaccines and biologics firm in India, to produce Takeda's dengue vaccine, TAK-003. The collaboration represents a significant advancement in combating the global public health menace of dengue fever, in accordance with the disease-specific objective established by the World Health Organisation (WHO) to attain a zero case-fatality rate from dengue by 2030.
Neglected Tropical Disease Treatment Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 3.61 Bn |
| Revenue Forecast In 2035 | USD 6.33 Bn |
| Growth Rate CAGR | CAGR of 6.00% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Drug Class, Disease Type, Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Omega Diagnostics Group PLC, Abbott, Oscar Medicare Pvt Ltd., Genome Diagnostics Pvt. Ltd., ZeptoMetrix and Other market players |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Neglected Tropical Disease Treatment Market :
Neglected Tropical Disease Treatment Market By Drug Class-
- Anti-Parasite
- Antifungal
- Antibiotics
- Others
Neglected Tropical Disease Treatment Market By Disease Type-
- Leishmaniasis
- Schistosomiasis
- Lymphatic Filariasis
- Chagas Disease
- African Trypanosomiasis
- Others
Neglected Tropical Disease Treatment Market By Distribution Channel-
- Direct Sales
- Indirect Sales
Neglected Tropical Disease Treatment Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Neglected Tropical Disease Treatment Market Size is valued at USD 3.61 billion in 2025 and is predicted to reach USD 6.33 billion by the year 2035.
The Neglected Tropical Disease Treatment Market is expected to grow at a 6.00% CAGR during the forecast period for 2026-2035.
Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Omega Diagnostics Group PLC, Abbott, Oscar Medicare Pvt Ltd., Genome Diagnostics Pvt. Ltd.,
neglected tropical disease treatment market is segmented based on drug class, disease type, distribution channel. As per the drug class, the market is classified into anti-parasite, antifungal, antibiotics, and others.
Asia Pacific region is leading the Neglected Tropical Disease Treatment Market